Stichworte
Behandlungsbedürftigkeit, Begutachtung ×
Ovarialtumoren ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

16 Suchergebnisse.

Eligibility Ovarian Cancer NCT01180504

- 12.09.18 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01180504 Sponsor: University Hospital Heidelberg Collaborator: Deutsche Krebshilfe e.V., Bonn (Germany) Information provided by: University Hospital Heidelberg Principal Investigator: Andreas Schneeweiss, MD Department of Gyneacology and Obstetrics, Unversity of Heidelberg Principal Investigator: Juergen Debus, MD, PhD Department of Radiation Oncology, University of Heidelberg

Eligibility Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck NCT01059643

- 03.09.18 - 1 Formular, 2 Itemgruppen, 13 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck; ODM derived from: https://clinicaltrials.gov/show/NCT01059643 Sponsor: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company

Eligibility Ovarian Neoplasms NCT00841191

- 15.08.18 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00841191

Eligibility Ovarian Carcinoma NCT00853307

- 14.08.18 - 1 Formular, 2 Itemgruppen, 28 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00853307

Eligibility Ovarian Carcinoma NCT00721890

- 14.08.18 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00721890

Eligibility Ovarian Cancer NCT00721162

- 14.08.18 - 1 Formular, 2 Itemgruppen, 34 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of Ramucirumab in Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00721162

Oral GW786034 treatment for ovarian cancer NCT00281632 - Screening Eligibility Criteria

- 14.04.18 - 1 Formular, 3 Itemgruppen, 31 Datenelemente, 1 Sprache
Itemgruppen: Header, Inclusion Criteria, Exclusion Criteria
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Eligibility Cancer NCT00756847

- 10.11.17 - 1 Formular, 2 Itemgruppen, 20 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00756847

Eligibility Ovarian Carcinoma NCT00474669

- 20.08.17 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Phase I Study of Intraperitoneal Hyperthermic Docetaxel; ODM derived from: https://clinicaltrials.gov/show/NCT00474669

Eligibility Ovarian Cancer NCT00132522

- 29.05.17 - 1 Formular, 2 Itemgruppen, 18 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide; ODM derived from: https://clinicaltrials.gov/show/NCT00132522

Eligibility Ovarian Carcinoma NCT01689714

- 25.11.16 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01689714

Eligibility Ovarian Neoplasms NCT00132704

- 18.11.16 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation; ODM derived from: https://clinicaltrials.gov/show/NCT00132704